The Board of Directors of the company is responsible for guiding the company's strategy, supervising the management team, making decisions on important matters, and being accountable to the company and its shareholders. They ensure that the Board of Directors exercises its powers in accordance with the law, the company's articles of incorporation, or resolutions of the shareholders' meeting. The Board of Directors is also responsible for the following:
The current (sixth) Board of Directors consists of seven directors, including three independent directors. Their term is from May 25, 2023, to May 24, 2025.
Current Position(s): Chairman, TTY Biopharm Company Limited
Ph.D., Economics, University of Illinois at Urbana-Champaign, USA
Director, TTY Biopharm Company Limited
Director, Dawan Technology Co., Ltd.
Director, American Taiwan Biopharm Co., Ltd.
PharmD, University of the Pacific Thomas J Long School of Pharmacy MBA, University of the Pacific Eberhardt School of Business
Supervisor, Da-Wan Technology Co., Ltd.
Taipei Medical University School of Pharmacy
Chairman and CEO, IROC Co., Ltd.
Independent Director, CCP Contact Probes Co., Ltd.
Independent Director, Radium Construction Co., Ltd.
Independent Director, Orient Pharma Co., Ltd.
Director, Taichung Bank Securities Co., Ltd.
Director, Chang Wah Electromaterials Inc.
Director, Super Dragon Technology Company Limited.
Director, ATrack Technology Inc.
Director, JMC Electronics Co., Ltd.
International MBA, University of St. Thomas, Minnesota State, USA
Current Position(s):Associate Professor, Department of Finance, National Chengchi University
Independent Director, CY Biotech Co.,Ltd.
Independent Director and Compensation Committee Member, Cooperative Bank Commercial Bank
Director, Catholic Cardinal Tien Hospital Foundation
Director, Foundation for the Development of National Chengchi University
Supervisor, Chinese Fiscal Association
Member, Review Committee for Complaints against Promotional Partnerships, Ministry of Finance
Member, Evaluation Committee for the Transfer of Business Operations to Private Enterprises, Ministry of Finance
Ph.D. in Economics from Virginia Polytechnic Institute and State University
Bachelor's degree in Physics from National Tsing Hua University
Dean of Kaohsiung Medical University
Professor of Pharmacy Kaohsiung Medical University
Chief Pharmacist of Kaohsiung Medical University Chung-Ho Memorial Hospital
PhD in Pharmacy, School of Pharmacy, Kaohsiung Medical University
MS in Pharmacy, School of Pharmacy, Kaohsiung Medical University
BS in Pharmacy, School of Pharmacy, Kaohsiung Medical University
Independent Director, Welgene Biotech Co., Ltd.
MBA, Columbia Business School, USA
Bachelor’s Degree in Biology, National Taiwan Normal University
According to Article 20 of our company's "Corporate Governance Best Practices," our diversity policy includes the following:
Professional Knowledge and Skills:
In the current (sixth) Board of Directors, there are seven directors, including three independent directors. The board members come from various fields, including industry, academic institutions, medical units, and financial and securities expertise, aligning with the company's "Corporate Governance Best Practices" on the diversity of board members in terms of knowledge, skills, and qualifications necessary for the company's development and execution of duties.
Based on our company's business model and strategic direction, directors with capabilities necessary for the company's stage of development are selected. This includes Chairman Chuan Lin, who has extensive experience in the government, academia, and international arena; Director Chou, Kang-Chi, who has a background in management; Director Wu Yong-Liang, with knowledge and experience in the pharmaceutical and biotech industry; Director Chou Te-Yu, with a wealth of financial experience; Independent Director Chen Rwei-Syun, who has a background in international financial institutions and biotech business development; Director Carl Hsiao, with a background in the US pharmaceutical market and sales channels; and Independent Director Huang Yaw-Bin, with extensive knowledge and background in the pharmaceutical and biotech industry.
Our company's implementation of diversity policies is as follows:
|Core Items||Nationality||Gender||Operation management||Leadership decision||Industry knowledge||Finance Accounting||Law|
|Independent director||Chou, Te-Yu||Taiwan||Male||V||V||V|
|Independent director||Chen, Rwei-Syun||Taiwan||Female||V||V||V||V|
|Independent director||Huang, Yaw-Bin||Taiwan||Female||V||V|
The current Board of Directors consists of 7 members with an average age of 61.33 years. The age distribution is as follows: 1 director aged 36-40, 3 directors aged 56-60, 1 director aged 61-65, 1 director aged 71-75, and 1 director aged 76-80.
In this term, there are no directors who hold the status of being employees of the company. There are two female directors, accounting for 28.5% of the board, which meets the target ratio of 28%. There are three independent directors, accounting for 42.9% of the board, and one independent director has a term of three terms.
The company places a strong emphasis on the diversity of the Board of Directors' composition. The target ratio for directors with a background in the securities and financial industry is 29%, and the current ratio is 42.85%.
In accordance with the company's established Corporate Governance Best Practices, the selection of Board of Directors members should consider diversity. The formulation of appropriate diversity policies should take into account the company's own operations, business model, and development needs. These policies include, but are not limited to, standards in the following two major aspects:
Basic Conditions and Values: Factors such as gender, age, nationality, and culture, with a target that the ratio of female directors should reach one-fourth of the total board seats.
Professional Knowledge and Skills: Consideration should be given to the professional backgrounds (e.g., legal, accounting, industry, finance, marketing, or technology), professional skills, and industry experiences of directors.
In 2023, the company conducted a comprehensive election of new Board of Directors members, all of whom met the qualification review and relevant regulations.
On March 22, 2016, the company established methods for evaluating the performance of the Board of Directors and functional committees. Through the assessment of control over company goals and missions, perception of responsibilities, engagement in operations, internal relationship management and communication, professional expertise, continuous learning, and internal controls, the effectiveness of the Board of Directors' operation was confirmed. These assessments also served as a basis for evaluating the performance of directors, providing reference for future director selection.
The company currently has department-level executives besides the Chairman and General Manager. To promote sustainable development and cultivate key talents in various fields, the company initiated the Talent Development Program (TDP) starting from 2012. This program is integrated into the company's Key Performance Indicators (KPIs) and aims to develop the top leadership in three professional areas: business, marketing, research and development, and management. Additionally, since 2022, the company has been consistently developing its core team, focusing on empowering leaders. A phased Empowerment Leadership Program was launched to plan the succession of key personnel in various departments.